Removing Tumor & Immune Cells from Blood

CATUVAB®: Using the proprietary ABCR-Technology to aggregate tumor cells and immune cells. CATUVAB is made to overcome the problems with donor blood in cancer surgeries and avoid the consequences of donor blood shortage as e.g. postponing of surgeries.

Powered by ABCR-T – Antibody Based Cell Removal Technology
Published in

ABCR-T: One Platform. Multiple Indications.

Our proprietary ABCR Technology uses a trifunctional antibody to selectively bind and aggregate tumor cells and immune cells. These aggregates can then be removed via filtration – enabling safer transfusions in both intraoperative and donor blood applications.

This platform opens multiple therapeutic possibilities:

Based on the clinacally proven technology, LBC is going to expand into further markets, which should be developed together with a strategic partner

For cancer surgeries

Introducing:
CATUVAB®

Lindis Blood Care has developed CATUVAB®, a groundbreaking medical device designed to avoid the adverse effects associated with donor blood transfusions during tumor surgeries.

By enabling the safe retransfusion of a patient’s own blood, CATUVAB® enhances patient outcomes and reduces reliance on donor blood.

Medical need

In major surgical procedures, significant blood loss can occur, often compensated by donor blood transfusions. However, these transfusions carry risks such as immune reactions and the transmission of infections.

Intraoperative blood salvage (IBS) enables the recovery and reuse of the patient’s own blood. However, this method is rarely used in oncological surgeries because tumor cells can remain in the blood.

CATUVAB® at a glance

Learn more about Catuvab®

Advantages of CATUVAB

LBC is the MedTech company which developed CATUVAB®, the first device to remove cancer cells and cancer stem cells of 14 major tumor indications from salvaged blood during cancer surgeries

Donor blood

Side effects of allogeneic blood

Access to autologous blood for groups
not allowed to accept allogeneic blood

Plannability of Surgeries

Allogeneic Blood

CATUVAB®

Allogeneic blood transfusion leads to increased costs* of € 800 – 1000 in average over all transfused patients which are avoided by use of CATUVAB®.

*Shander et al 2007

About Lindis Bloodcare

Founded in 2018, Lindis Blood Care is a MedTech company dedicated to making blood transfusions safer and more accessible.

With our Antibody-Based Cell Removal Technology (ABCR-T), we develop innovative solutions to remove tumor and immune cells from blood — improving patient outcomes and transforming transfusion practices worldwide.

Key Facts

Founded

2018, Germany

Technology

ABCR-T (Antibody-Based Cell Removal)

Markets

EU, US (FDA submited), Asia expansion in preparation

Clinical validation

REMOVE study, 136 patients across multiple centers

Latest News

New Multicenter Study Confirms: CATUVAB® Safely Removes Tumor Cells from Salvaged Blood

5 days ago

Successful Financing

9 months ago

Positive Top Line Results

1 year ago

Top Line Results presentation at NATA24

1 year ago

Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study

2 years ago

Lindis Blood Care Establishes Scientific Advisory Board of Leading Industry Experts

3 years ago